睿知中国疾病研究地图
候选清单0

正在招募食管鳞状细胞癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07463573,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Has histologically or cytologically documented unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) according to American Joint Committee on Cancer 8th edition staging system on ESCC.

    入选标准第 9 条

  3. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0 (v6.0);

    入选标准第 8 条

    Having previously received B7-H3-targeted therapy.

    排除标准第 7 条

    Having received treatment with systemic corticosteroids (prednisone at >10 mg/day, or similar drugs at equivalent dose) or other immunosuppressive agents within 14 days prior to randomization;

    排除标准第 13 条

  4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 within 7 days before the first dose;

    入选标准第 3 条

  5. Diagnosis of other primary malignancies within 5 years prior to signing the informed consent form.

    排除标准第 1 条

  6. A serum pregnancy test must be performed within 7 days prior to randomization for premenopausal women of childbearing potential, and the result must be negative and must not be lactating;

    入选标准第 5 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07463573,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily consent to participate in this study and sign the informed consent form.
  2. Males and females aged ≥18 years old;
  3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 within 7 days before the first dose;
  4. Estimated survival time of more than 3 months.
  5. A serum pregnancy test must be performed within 7 days prior to randomization for premenopausal women of childbearing potential, and the result must be negative and must not be lactating;
  6. All enrolled patients and the partners should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.
  7. Capable of understanding trial requirements, willing and able to comply with trial and follow-up procedures.
  8. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0 (v6.0);
  9. Has histologically or cytologically documented unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) according to American Joint Committee on Cancer 8th edition staging system on ESCC.
  10. Has at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) as assessed by the investigator.
  11. Sufficient bone marrow and organ function.

排除标准:Exclusion Criteria:

  1. Diagnosis of other primary malignancies within 5 years prior to signing the informed consent form.
  2. Having histologically or cytologically confirmed adenosquamous carcinoma subtype.
  3. Brain metastases (unless asymptomatic and no progression confirmed by imaging ≥4 weeks prior to randomization);
  4. Presence of leptomeningeal metastases or brainstem metastases;
  5. Spinal cord compression (identified via imaging, regardless of symptoms);
  6. Previous or ongoing treatment with topoisomerase I inhibitors
  7. Having previously received B7-H3-targeted therapy.
  8. Being ineligible to any chemotherapies in the control arm due to prior progression or intolerance.
  9. Insufficient washout of prior anticancer therapies prior to randomization.
  10. Having underwent major organ surgery (excluding biopsy) or significant trauma within 4 weeks prior to randomization;
  11. Requiring elective surgery during the study.
  12. Having received live vaccine or live attenuated vaccine within 4 weeks before study randomization.
  13. Having received treatment with systemic corticosteroids (prednisone at >10 mg/day, or similar drugs at equivalent dose) or other immunosuppressive agents within 14 days prior to randomization;
  14. Moderate to severe pulmonary disease significantly impairing lung function, including idiopathic pulmonary fibrosis, autoimmune/connective tissue disorders with lung involvement, or prior pneumonectomy.
  15. Having a history of interstitial lung disease (ILD)/ non-infectious pneumonitis that required corticosteroids, current ILD/ non-infectious pneumonitis, or suspected ILD/ non-infectious pneumonitis that cannot be ruled out by imaging at screening;
  16. Active tuberculosis;
  17. Autoimmune diseases not in clinical remission, other acquired or congenital immunodeficiency diseases,
  18. A history of allogeneic stem cell, bone marrow, or organ transplantation.
  19. Serious infections (e.g., bacteremia, or severe pneumonia) within 4 weeks prior to randomization;
  20. active infection requiring systemic antibiotic therapy within 1 weeks prior to randomization;
  21. Has positive results in virus serology tests (hepatitis B virus infection participants receiving antiviral treatment other than interferon are allowed to be enrolled);
  22. Uncontrolled or significant cardiovascular disease.
  23. Clinically uncontrolled third-space effusion.
  24. Known hypersensitivity to investigational product components, analogues, or control drugs (e.g., docetaxel, paclitaxel, irinotecan hydrochloride).
  25. Drug abuse;
  26. Any other medical conditions that may interfere with study participation or the results of the clinical study as per the discretion of investigator;
  27. Has alcohol or drug dependence.
  28. Poor compliance as per investigator discretion;
  29. Has a history of other serious systemic diseases.

引自 ClinicalTrials.gov, NCT07463573, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07463573,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07463573